DelveInsight’s, “Severe Hypertriglyceridemia Pipeline Insight 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Severe Hypertriglyceridemia Pipeline. Dive into DelveInsight’s comprehensive report today! @ Severe Hypertriglyceridemia Pipeline Outlook

 

Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report

• August 2024:- Ionis Pharmaceuticals- An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG). This is a multi-center, open-label study of up to 700 participants with SHTG who would be rolled over from studies ISIS 678354-CS5 (NCT05079919) or ISIS 678354-CS6 (NCT05552326). Day 1 of this study may be same as the Week 53 visit of either ISIS 678354-CS5 or ISIS 678354-CS6, as applicable. Participants will receive olezarsen during the 53-week treatment period. The study will include a 31-day qualification Period, a 53-week treatment period, and a 13-week post-treatment period.
• DelveInsight’s Severe Hypertriglyceridemia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Severe Hypertriglyceridemia treatment.
• The leading Severe Hypertriglyceridemia Companies such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.
• Promising Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.

 

Stay ahead with the most recent pipeline outlook for Severe Hypertriglyceridemia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Severe Hypertriglyceridemia Treatment Drugs

 

Severe Hypertriglyceridemia Emerging Drugs Profile

• ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. Currently, it is in Phase II stage of clinical trial evaluation to treat Severe Hypertriglyceridemia.

 

• Olezarsen: Ionis Pharmaceuticals

Olezarsen, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of apoC-III in the liver. ApoC-III is a protein that regulates triglyceride metabolism in the blood by inhibiting lipoprotein lipase that breakdown triglycerides and by preventing clearance of triglyceride-rich lipoproteins. ApoC-III is an independent risk factor for both pancreatitis and cardiovascular disease.

 

Explore groundbreaking therapies and clinical trials in the Severe Hypertriglyceridemia Pipeline. Access DelveInsight’s detailed report now! @ New Severe Hypertriglyceridemia Drugs

 

Severe Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

 

Severe Hypertriglyceridemia Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

 

Unveil the future of Severe Hypertriglyceridemia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Severe Hypertriglyceridemia Market Drivers and Barriers

 

Scope of the Severe Hypertriglyceridemia Pipeline Report

• Coverage- Global
• Severe Hypertriglyceridemia companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others.
• Severe Hypertriglyceridemia Therapies such as Olezarsen, Plozasiran Injection, and others.
• Severe Hypertriglyceridemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Severe Hypertriglyceridemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Severe Hypertriglyceridemia Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Severe Hypertriglyceridemia Companies, Key Products and Unmet Needs

 

Table of Content

1. Introduction
2. Executive Summary
3. Severe Hypertriglyceridemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Severe Hypertriglyceridemia – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Olezarsen: Ionis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ARO-APOC3: Arrowhead Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Severe Hypertriglyceridemia Key Companies
21. Severe Hypertriglyceridemia Key Products
22. Severe Hypertriglyceridemia- Unmet Needs
23. Severe Hypertriglyceridemia- Market Drivers and Barriers
24. Severe Hypertriglyceridemia- Future Perspectives and Conclusion
25. Severe Hypertriglyceridemia Analyst Views
26. Severe Hypertriglyceridemia Key Companies
27. Appendix 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services